Cell line · CVCL_1279
Papers69
1 to 20 of 69
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Epigenetic Activation of ANGPTL4 Drives EBV-Negative Gastric Cancer via Neutrophil Recruitment and NET Release via Stabilizing ANXA5. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhanced Antitumor Effects of 5-Fluorouracil and a Vagal Nerve Blocker Loaded in a Thermosensitive Hydrogel for Localized Drug Delivery in Gastric Cancer. | Pharmaceutics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Calcitriol alleviates ARID2-deficient gastric cancer metastasis via inhibition of the Wnt/β-catenin signaling pathway. | Transl Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery and Optimization of AMT-676, a CDH17-Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mutation-Immune Crosstalk Contextualizes CAF-Associated ARPC1A Programs and Cisplatin Response in Gastric Cancer. | Hum Mutat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| METTL7A Downregulation Drives SLC1A5-Mediated Glutamine Competition to Promote Tumor Proliferation and Suppress CD8+ T Cell Immunity in Gastric Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TMEM97 regulates cholesterol biosynthesis and mitochondrial metabolism in gastric carcinoma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Long non-coding RNA SOCS2-AS1 inhibits gastric cancer progression via the miR-324-3p/GRIK3 axis: a mechanistic study. | World J Surg Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PARG Governs a PARylation-Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination-Mediated Chemoresistance. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of 5'-tiRNAGly restores anti-PD-1 immunotherapy efficacy via DLST-mediated OGDHL succinylation in gastric cancer. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ABCG2 Contributes to Multidrug Resistance and Aggressive Phenotypes Associated with ERK Signaling in Gastric Cancer. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The vesicle transport gene SEC23A is a novel prognostic indicator and therapeutic target in gastric cancer. | Front Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing platinum-based chemotherapy efficacy and safety through combination therapy-mediated remodeling of autophagic homeostasis in gastric cancer. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| OTUB2 induces M2 tumor-associated macrophage polarization and increases CD274 expression in gastric cancer cells to aggravate the progression of gastric cancer. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GAL3ST1-Mediated Histone Tyrosine Sulfation Induced by Cancer-Associated Fibroblasts Promotes Gastric Cancer Metastasis. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PIK3R1 as a Gastric Cancer Biomarker Linked to CD73 + Treg-Mediated Immunosuppression. | Oncol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing the antitumor efficacy using a combination of FGFR4 Inhibitor (H3B-6527) and oxaliplatin in gastric cancer. | Neoplasia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Development of Novel PANoptosis-Related Gene Signatures to Predict the Prognosis of Patients With Stomach Adenocarcinoma. | Hum Mutat | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1279/papers